Update: A late-stage company in early-stage clothing
Thanks to the license agreement with Brighthaven Ventures (“BHVâ€), Islet has catapulted to late-stage status, with two Phase IIb programmes for major indications (type II diabetes and NASH). Importantly, remogliflozin etabonate (remo) has the potential to be a best-in-class SGLT2 inhibitor.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.